Document Detail


Leibenstein on the benefits and costs of birth control programmes.
MedLine Citation:
PMID:  22073998     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Abstract Enke draws attention particularly to his recent dynamic models of the effects of birth prevention. He argues that the result of birth prevention is, typically, to leave future G.N.P. almost unaffected, with a smaller population and a reduction in the ratio of dependent children to the active age groups. G.N.P. per head is thus raised. Leibenstein accepts the relevance of population control and family planning programmes. He argues, however, that in its present form benefit-cost analysis does not provide a sound basis for estimating the value of such programmes.
Authors:
S Enke; H Leibenstein
Related Documents :
18046798 - Evaluating consistency of best professional judgment in the application of a multiple l...
1032298 - Ecdin, an ec data bank for environmental chemicals.
19209368 - Aluminium siting in the zsm-5 framework by combination of high resolution 27al nmr and ...
2683218 - First generation of a new science: risk assessment in transition.
22797028 - A method for the semantic enrichment of clinical trial data.
23607168 - Script, code, information: how to differentiate analogies in the "prehistory" of molecu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Population studies     Volume:  24     ISSN:  0032-4728     ISO Abbreviation:  Popul Stud (Camb)     Publication Date:  1970 Mar 
Date Detail:
Created Date:  2011-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376427     Medline TA:  Popul Stud (Camb)     Country:  England    
Other Details:
Languages:  eng     Pagination:  115-20     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Malaria eradication and the fall of mortality.
Next Document:  Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.